Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Solentim Ltd
Solentim Ltd
Activities:
Analysis
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Cell-based therapy specialist Solentim expands European operations
The England-based company has established a new EU entity based in Ireland to facilitate frictionless business within the EU
Finance
Solentim expands operations to China
“This direct investment will help us support and expand our activities,” said General Manager of Solentim China, Kun Peng
Research & Development
Solentim launches workflow for single stem cell cloning
The company aims to create, isolate and characterise the highest value cells for biological medicine development
Manufacturing
Solentim names new Chief Marketing Officer
Dr Mark Truesdale will join the cell line development (CLD) instrumentation specialist
Pharmaceutical
Solentim and SAL Scientific partner on cell line development
Collaboration will add SAL’s new growth supplements for cell culture media to Solentim's offerings
Finance
Research funding round-up
Capital to support the development of new drugs and technology around the world
Manufacturing
Simple, single-use TFF solution for R&D or manufacturing
Solentim claims significant time-saving advantages are provided by its new systems
Subscribe now